Please login to the form below

Not currently logged in
Email:
Password:

EGFR-mutation

This page shows the latest EGFR-mutation news and features for those working in and with pharma, biotech and healthcare.

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress. ... Approximately a quarter of global lung cancer cases are EGFR-mutated, although in Asia the rate can climb to over 40% of new cases.

Latest news

More from news
Approximately 2 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

  • Harnessing complexity Harnessing complexity

    While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....